Remove 2003 Remove Treatment Remove Vaccine
article thumbnail

PFIZER ANNOUNCES RETIREMENT OF CHIEF FINANCIAL OFFICER FRANK D’AMELIO

The Pharma Data

Mike McDermott has been with Pfizer for 18 times having started with the Company in 2003 as head of also Wyeth’s Biotech Manufacturing Operations at its Pearl River, New York point. As a result of his sweats, Pfizer expects to achieve the thing of producing 3 billion boluses of COVID-19 vaccines in 2021 and 4 billion boluses in 2022.

Vaccine 52
article thumbnail

Women in Stem with Andrea Pfeifer

Drug Target Review

Then I was approached to co-found AC Immune in 2003. Food and Drug Administration for our Alzheimer’s vaccine candidate, ACI-24.060. COVID-19 has shown the revolutionary impact of vaccines. My family and friends said I was crazy to take this step. People with Down syndrome are an important addition to the clinical study.

Disease 95
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Antibody-drug conjugates payloads: then, now and next

Drug Target Review

Antibody-drug conjugates (ADCs) have been a groundbreaking approach to cancer treatment with their ability to deliver cytotoxic drugs directly to diseased cells while sparing healthy tissues. 10 Proteasome inhibitors Since the approval of Bortezomib in 2003, 11 new proteasome inhibitors have emerged with reduced side effects.

article thumbnail

U.S. FDA ACCEPTS FOR PRIORITY REVIEW

The Pharma Data

FDA ACCEPTS FOR PRIORITY REVIEW PFIZER’S APPLICATION FOR TICOVAC (TICK-BORNE ENCEPHALITIS VACCINE). If approved, the vaccine may help reduce the risk of TBE for people traveling to endemic areas, potentially including military personnel serving in these locations. 1,2 If approved, TicoVac would be the first vaccine in the U.S.

FDA 52
article thumbnail

Enlisting Monoclonal Antibodies in the Fight Against COVID-19

NIH Director's Blog: Drug Development

Because of these and other factors, many experts think antibody-based therapies may offer one of the best near-term options for developing safe, effective treatments for COVID-19. 18 May 2020 [Epub ahead of print] [4] Accelerating COVID-19 therapeutic interventions and vaccines (ACTIV): An unprecedented partnership for unprecedented times.

Virus 52
article thumbnail

Eclectic Genomics: Cat Flu, Dolphin Adaptation to Climate Change, Predicting Cancer, and Diagnosing Rare Disease

PLOS: DNA Science

That information led, thanks to vaccine shelved from the first SARS circa 2003, to the rapid development and deployment of mRNA vaccines against the new infectious disease. These patterns can foretell which treatments will likely work and which won’t, how likely and quickly the cancer will spread, and its path in the body.

Disease 98
article thumbnail

China’s National Medical Products Administration approves Benlysta (belimumab) for adult patients with active lupus nephritis

The Pharma Data

GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that China’s National Medical Products Administration (NMPA) has approved Benlysta (belimumab) for the treatment of adult patients with active lupus nephritis (LN) who are receiving standard of care. About lupus. Benlysta China Indication.